Adaptimmune Therapeutics Statistics
Total Valuation
ADAP has a market cap or net worth of $20.73 million. The enterprise value is $43.35 million.
Important Dates
The last earnings date was Wednesday, August 13, 2025, before market open.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ADAP has 265.05 million shares outstanding. The number of shares has increased by 8.53% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 265.05M |
| Shares Change (YoY) | +8.53% |
| Shares Change (QoQ) | +2.75% |
| Owned by Insiders (%) | 0.66% |
| Owned by Institutions (%) | 10.72% |
| Float | 185.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.31 |
| Forward PS | 0.46 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.52
| Current Ratio | 1.52 |
| Quick Ratio | 0.69 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.10 |
Financial Efficiency
Return on equity (ROE) is -1,341.10% and return on invested capital (ROIC) is -152.32%.
| Return on Equity (ROE) | -1,341.10% |
| Return on Assets (ROA) | -40.86% |
| Return on Invested Capital (ROIC) | -152.32% |
| Return on Capital Employed (ROCE) | -186.89% |
| Revenue Per Employee | $128,626 |
| Profits Per Employee | -$335,486 |
| Employee Count | 506 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 24.04 |
Taxes
In the past 12 months, ADAP has paid $3.71 million in taxes.
| Income Tax | 3.71M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.83% in the last 52 weeks. The beta is 2.18, so ADAP's price volatility has been higher than the market average.
| Beta (5Y) | 2.18 |
| 52-Week Price Change | -92.83% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.43 |
| Relative Strength Index (RSI) | 30.08 |
| Average Volume (20 Days) | 54,445,729 |
Short Selling Information
| Short Interest | 8.35M |
| Short Previous Month | 3.88M |
| Short % of Shares Out | 3.81% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.67 |
Income Statement
In the last 12 months, ADAP had revenue of $65.09 million and -$169.76 million in losses. Loss per share was -$0.66.
| Revenue | 65.09M |
| Gross Profit | -87.43M |
| Operating Income | -147.87M |
| Pretax Income | -162.17M |
| Net Income | -169.76M |
| EBITDA | -137.24M |
| EBIT | -147.87M |
| Loss Per Share | -$0.66 |
Full Income StatementBalance Sheet
The company has $26.06 million in cash and $48.68 million in debt, giving a net cash position of -$22.62 million or -$0.09 per share.
| Cash & Cash Equivalents | 26.06M |
| Total Debt | 48.68M |
| Net Cash | -22.62M |
| Net Cash Per Share | -$0.09 |
| Equity (Book Value) | -70.96M |
| Book Value Per Share | -0.27 |
| Working Capital | 26.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$190.03 million and capital expenditures -$1.64 million, giving a free cash flow of -$191.67 million.
| Operating Cash Flow | -190.03M |
| Capital Expenditures | -1.64M |
| Free Cash Flow | -191.67M |
| FCF Per Share | -$0.72 |
Full Cash Flow StatementMargins
Gross margin is -134.32%, with operating and profit margins of -227.19% and -260.82%.
| Gross Margin | -134.32% |
| Operating Margin | -227.19% |
| Pretax Margin | -255.12% |
| Profit Margin | -260.82% |
| EBITDA Margin | -210.86% |
| EBIT Margin | -227.19% |
| FCF Margin | n/a |
Dividends & Yields
ADAP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.53% |
| Shareholder Yield | -8.53% |
| Earnings Yield | -819.01% |
| FCF Yield | -924.72% |
Analyst Forecast
The average price target for ADAP is $1.02, which is 1,204.35% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.02 |
| Price Target Difference | 1,204.35% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 9.89% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |